CREDENCE: A New Perspective Primary Care | Diabetes on the Net

Diabetes on the Net is intended for healthcare professionals

This promotional webcast has been developed by Napp Pharmaceuticals Limited and Napp products will be discussed. Napp has fully funded the meeting and is responsible for the content, logistics and selection of speakers. OmniaMed has provided editorial, marketing and logistical support.

primary care

CREDENCE:
Type 2 Diabetes Management
- A New Perspective

Protect the kidney to protect the heart

Join us for our upcoming online webcast taking place on
22 July 2020 at 12.30 and 19.00

Taking place online

What does the CREDENCE trial mean for the management of diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM) for primary care?

In this promotional webcast, aimed specifically at primary care, we will take a critical look at the CREDENCE trial and assesses how Invokana® (canagliflozin) can be utilised for the management of DKD in T2DM.

By attending, you will gain unique insight into:
  • The recent licence extension to Invokana
  • How the licence change could change your management of DKD in T2DM
  • Kidney function, its assessment and the interpretation of common tests.

This webcast has a very practical focus, and we believe it will be of great benefit to all primary care healthcare professionals wishing to know more about DKD in T2DM (see the agenda below for full details).

This 80-minute broadcast includes a 20-minute live Q&A, where you will be able to ask your questions to the speakers, and will be broadcast twice, at 12.30 and 19.00 on 22 July 2020.

Join us for our upcoming online webcast

Taking place on 22 July 2020

12.30 and 19.00

Your Speakers

Dr Kevin Fernando

GP, North Berwick, near Edinburgh

Dr Kevin Fernando is a part-time GP Partner and GP Educational Supervisor working at the coalface in North Berwick Health Centre, near Edinburgh. Dr Fernando is also Scottish Lead for the Primary Care Diabetes Society, and an observer member of the Primary Care Cardiovascular Society.  His other roles include Royal College of General Practitioners Clinical Advisor for Diabetes and Multimorbidity, and Education Director for GPNotebook Education.

Dr Fernando graduated from the University of Edinburgh in 2000. He holds both MRCGP and MRCP(UK) qualifications, and has completed a Masters degree in diabetes which he passed with distinction.

Dr Fernando has been elected to the Fellowship of the Royal College of General Practitioners, the Royal College of Physicians of Edinburgh and the Academy of Medical Educators for his work in diabetes and medical education.

Dr Amrit Lamba

GP and Partner at Colindale Medical Centre, London

Dr Amrit Lamba is a GP Partner at Colindale Medical Centre in Barnet Clinical Commissioning Group. He is also a lead clinician for the Barnet Federated GPs Diabetes Network and a board member for the Community Diabetes Service.

Dr Lamba is a clinical cluster lead for the Barnet Federated GPs Research Network, supporting local primary care participation in national research projects.  In 2017, Dr Lamba founded the Barnet Diabetes Forum, which hosted regular educational events and networking opportunities for primary care clinicians with an interest in diabetes.

Professor David Wheeler

Honorary Consultant Nephrologist, Professor of Kidney Medicine, Royal Free, London

Professor David Wheeler’s current positions include Professor of Kidney Medicine at University College London, Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust and Honorary Professorial Fellow of the George Institute for Global Health, Sydney, Australia. He is a Clinician Scientist with an interest in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has contributed to the development and running of several large-scale clinical trials involving patients with chronic kidney disease including SHARP, EVOLVE and CREDENCE. He is currently co-chief investigator of the DAPA-CKD study.

Locally, Professor Wheeler heads the clinical research team at the Centre for Nephrology, Royal Free Hospital in London. He has been involved in Clinical Practice Guideline Development for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO), of which he is currently co-chair. He has served terms as President of the UK Renal Association, Chair of the UK Renal Registry and Associate Editor of Nephrology Dialysis Transplantation (NDT).

Agenda

22 July 2020

Session 1 (10 mins)

Chair's introduction
Current management of DKD in type 2 diabetes

Setting the scene

  • Cardiovascular and renal outcome studies to date
  • The importance of kidney protection
  • The need: early renal protection in primary care

Dr Kevin Fernando
(chair)

Session 2 (20 mins)

Bringing CREDENCE to life: what does the data show?

  • Study background and design
  • What does this data add?
  • Practical implications of CREDENCE
    • Cases illustrating how practice may change in light of the licence extension
    • Dosing considerations

Prof David Wheeler

Session 3 (30 mins)

Management of DKD in type 2 diabetes –
past present and future: CREDENCE in context

  • How to assess kidney function
    • eGFR and ACR
  • Practical considerations for ordering tests
  • Who do we test and how do we interpret the results?
  • When is canagliflozin an appropriate option?

Dr Amrit Lamba

Session 4 (20 mins)

Live Q&A

Moderated by the Chair

Book your place on our upcoming webcast

What does the CREDENCE trial mean for the management of diabetic kidney disease in type 2 diabetes for primary care?

22 July 2020

12.30 and 19.00

Days
Hours
Min
Sec

Upcoming webcast

A promotional webcast from
Napp Pharmaceuticals Limited

Specialist Care
Type 2 Diabetes Management -
A New Perspective​

Protect the kidney to protect the heart
21 July 2020
Days
Hours
Min
Sec

In association with

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk
Adverse events should also be reported to Napp Pharmaceuticals at drugsafetyuk@napp.co.uk

Date of preparation: July 2020 UK/INV-20106j

Complete the registration form

Your data is being collected by OmniaMed Communications on behalf of Napp Pharmaceuticals Limited solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Napp.
This promotional webcast has been developed by Napp Pharmaceuticals Limited and Napp products will be discussed. Napp has fully funded the meeting and is responsible for the content, logistics and selection of speakers. OmniaMed has provided editorial, marketing and logistical support.
Date of preparation: July 2020 UK/INV-20106j

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

See you on 22 July 2020

Days
Hours
Minutes
Seconds

Thanks for registering!

This promotional webcast has been developed by Napp Pharmaceuticals Limited and Napp products will be discussed. Napp has fully funded the meeting and is responsible for the content, logistics and selection of speakers. OmniaMed has provided editorial, marketing and logistical support.
UK/INV-20106j – Date of preparation: July 2020